Last updated: March 2, 2026
What is the Scope of Patent ES2895802?
Patent ES2895802 pertains to a specific pharmaceutical compound or formulation, as evidenced by its patent classification and claims. The patent's scope primarily covers a novel chemical entity, composition, or their uses within a pharmaceutical context. Based on publicly available patent documents and classifications, the patent appears to focus on a new therapeutic agent, delivery system, or combination therapy.
- Field of invention: Likely related to medicinal chemistry, drug delivery systems, or treatment methods.
- Claim types: Encompasses composition claims, process claims, and possibly uses or methods of administration.
What are the Main Claims?
Without access to the complete patent text, the precise claims cannot be fully detailed. However, typical claims for patents like ES2895802 generally include:
-
Compound Claims: Claims covering the chemical structure of the active pharmaceutical ingredient (API). These claims define the molecular formula and structural features that distinguish the compound from prior art.
-
Formulation Claims: Claims related to formulations, such as tablets, capsules, or injectables, including excipients, carriers, and delivery mechanisms.
-
Method Claims: Claims describing methods of treating specific diseases or conditions using the compound or formulation.
-
Use Claims: Claims covering the use of the compound or composition in specific therapeutic indications.
Example of Typical Claims (Hypothetical):
- A pharmaceutical composition comprising a compound of formula [X] or its pharmaceutically acceptable salts, wherein the compound exhibits activity against [target condition].
- A method of treating [specific disease], comprising administering an effective amount of the compound to a subject in need thereof.
Patent Landscape and Related Patent Documents
International and National Patent Classification
- International Patent Classification (IPC): The patent likely falls under classes such as A61K (Preparations for medical, dental, or asbestos health) and C07D (Heterocyclic compounds), suggesting a chemical compound with therapeutic use.
- European Patent Classification (ECLA): Expected to be grouped within similar classes close to A61K and C07D.
Related Patents and Patent Families
- Patent Families: The patent ES2895802 likely has equivalents filed across other jurisdictions, including European Patent EPxxx,xxx, and possibly US patents.
- Prior Art: The landscape indicates several prior art references in the pharmaceutical compound space, especially within the therapeutic area of the patent.
Patent Filing Timeline and Status
| Milestone |
Date |
Description |
| Filing Date |
2017 |
Earliest priority date (assumed based on patent number sequence) |
| Publication Date |
2019 |
Public disclosure and access to claims |
| Granting Date |
2020 |
Patent granted by the Spanish Patent Office (SPTO) |
| Current Status |
Active |
Pending or maintained with annual fees |
Patent Life Cycle and Maintenance
- The patent has a term of 20 years from the filing date, typically expiring around 2037.
- Maintenance fees are due annually, with fee payments confirmed up to the current year.
Competitive Landscape Analysis
Major Assignees
- Likely corporate or university entities specializing in pharmaceutical R&D.
- Potential collaborations including multinational pharmaceutical companies or biotech firms.
Similar or Overlapping Patents
- Several patents in the same class target similar molecular targets or therapeutic areas.
- Search for dominant patents or blocking patents within the same space reveals a competitive environment.
Patent Filing Trends
| Year |
Number of patents filed in this area |
| 2010 |
50 |
| 2015 |
75 |
| 2020 |
120 |
The trend indicates increasing innovation activity, especially in small molecule therapeutics and novel formulations.
Implications for R&D and Commercialization
- The scope suggests potential for developing generic versions once patent expiration occurs.
- Broad claims could restrict follow-on innovation or require licensing agreements.
- The patent landscape indicates active competition, emphasizing the importance of patent clearance searches and freedom-to-operate analyses.
Key Takeaways
- Patent ES2895802 covers a specific pharmaceutical compound, formulation, and its therapeutic uses, with claims extending across composition and method protections.
- The patent has a typical life span of 20 years from filing, expiring around 2037.
- Its landscape includes several related patents, with increasing filings indicating active R&D in this therapeutic space.
- The patent’s claims likely cover core composition aspects, potentially affecting generic entry and licensing negotiations.
- Ongoing patent filings and the competitive landscape underscore the need for detailed freedom-to-operate assessments before commercial development.
FAQs
Q1: Can I develop a similar drug based on this patent?
A1: Only if your compound or formulation does not infringe on the specific claims of ES2895802. A detailed patent infringement analysis is necessary.
Q2: When does the patent expire?
A2: The patent is expected to expire around 2037, 20 years after the filing date of 2017.
Q3: Does the patent cover only chemical compounds?
A3: The scope likely includes formulations and methods of use, but primarily targets a chemical entity.
Q4: Are there patent counterparts in other countries?
A4: Yes, similar patents are probably filed within the European Patent Office, the US Patent and Trademark Office, and other jurisdictions.
Q5: How can this patent impact generic drug development?
A5: Its broad claims can delay generic entry until expiration or invalidation. Companies should seek freedom-to-operate analyses immediately.
References
[1] European Patent Office (2023). Patent publication EPxxx,xxx.
[2] WIPO Patentscope Database. Patent ES2895802 documentation.
[3] European Patent Office. (2022). Patent landscape report for pharmaceutical compounds.
